#CureLGMDR1

C3 is Building Scientific Leadership

Coalition to Cure Calpain 3 is leading the charge to assemble the best scientific minds to solve limb-girdle muscular dystrophy type 2A (LGMD2A/R1). In celebration of ten years of progress in our mission to fund research for a cure and build

C3 Celebrates a Decade of Achievement

Coalition to Cure Calpain 3 (C3) has come a long way in ten years in driving science and awareness to treat limb girdle muscular dystrophy, type 2A (known as LGMD2A/R1, LGMD R1 Calpain 3 related, or calpainopathy). In celebration of ten

Care Questionnaire Study for the LGMDs – Your help is needed!

The following is being shared on behalf of Lindsay Alfano, PT, DPT, PCS, Nationwide Children’s Hospital. The goal of the “Care Questionnaire Study for the LGMDs” is to understand current care practices for diagnosis and management of care for individuals

Notes from 23rd annual meeting of the American Society for Gene and Cell Therapy

The American Society for Gene and Cell Therapy (ASGCT) annual meeting kicked off on Tuesday, May 12, 2020. Due to COVID-19, the meeting was held virtually. This meeting covers the field’s latest and most innovative science across all diseases and

May 20 is Clinical Trials Day

Clinical Trials Day occurs every year on May 20 to recognize the people who conduct clinical research trials and to provide an opportunity to raise awareness of clinical trials. This date was chosen to commemorate the day that James Lind

Join Coalition to Cure Calpain 3 in celebrating Rare Disease Day!

Rare Disease Day takes place on the last day of February every year, with the goal of raising awareness about rare diseases and their impact on patients’ lives. Over 300 million people are living with one or more of over

C3 Grant Awardee Featured in LGMD Awareness Day Spotlight Interview

Coalition to Cure Calpain 3 (C3) has recently awarded a research grant to Dr. Antoine Dufour. The project, titled ‘Unbiased Systems-wide Investigation of Calpain 3 in Patients with LGMD2A/R1 Using Mass Spectrometry,’ aims to better understand the biological role of

2019 – The C3 Year In Numbers

2019 was a busy year for Coalition to Cure Calpain 3! During the past year we: • Funded two new research projects: Funding was awarded to Dr. Jaakko Sarparanta, Folkhälsan Research Center and the University of Helsinki, and Dr. Nicholas

Promising Insights into Safety of LGMD2A/R1 Gene Therapy Approach

Published research alert: Titin splicing regulates cardiotoxicity associated with Calpain-3 gene therapy for LGMD2A/R1 Coalition to Cure Calpain 3 (C3) is pleased to announce the publication of research undertaken by Dr. Isabelle Richard, Head of the Progressive Dystrophy Laboratory, Généthon,

Double your donation on Giving Tuesday 2019

A “C3 Champion” has made a commitment to match every dollar donated on Giving Tuesday, up to $25,000. Your contribution today to support scientific research for those families impacted by the muscle-wasting disease LGMD2A/R1 (a form of calpainopathy)